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Abstract
Background: Neurological soft signs are subtle but observable impairments in motor and sensory functions that
are not localized to a specific area of the brain. Neurological soft signs are common in schizophrenia. It has been
established that soft signs meet two of five criteria for an endophenotype, namely: association with the illness, and
state independence. This review investigated whether soft signs met a further criterion for an endophenotype,
namely familial association. It was hypothesized that if familial association were present then neurological soft signs
would be: (a) more common in first-degree relatives of people with schizophrenia than in controls; and (b) more
common in people with schizophrenia than in their first-degree relatives.
Method: A systematic search identified potentially eligible studies in the EMBASE (1980-2011), OVID - MEDLINE
(1950-2011) and PsycINFO (1806-2011) databases. Studies were included if they carried out a three-way comparison
of levels of soft signs between people with schizophrenia, their first-degree relatives, and normal controls. Data
were extracted independently by two reviewers and cross-checked by double entry.
Results: After screening 8678 abstracts, seven studies with 1553 participants were identified. Neurological soft signs
were significantly more common in first-degree relatives of people with schizophrenia than in controls (pooled
standardised mean difference (SMD) 1.24, 95% confidence interval (c.i) 0.59-1.89). Neurological soft signs were also
significantly more common in people with schizophrenia than in their first-degree relatives (SMD 0.92, 95% c.i 0.64-
1.20). Sensitivity analyses examining the effects of age and group blinding did not significantly alter the main
findings.
Conclusions: Both hypotheses were confirmed, suggesting that the distribution of neurological soft signs in
people with schizophrenia and their first-degree relatives is consistent with the endophenotype criterion of familial
association.
Background
Neurological soft signs are subtle but observable impair-
ments in motor and sensory functions that are not loca-
lized to a specific area of the brain nor characteristic of
any specific neurological condition [1]. Typically they
are classified into signs relating to: motor co-ordination,
sequencing of complex motor tasks, sensori-motor inte-
gration, and disinhibition [2]. Neurological soft signs are
known to correlate with a range of neuro-cognitive and
neuro-anatomical abnormalities, and it has been
proposed that they represent an underlying defect in
neural integration [3]. Until recently neurological soft
signs have been considered of little practical clinical sig-
nificance, but the prospect that they could be an endo-
phenotype of schizophrenia has led to a resurgence of
interest [4].
Endophenotypes are defined as trait-markers that are
present independent of the manifestation of a disease
[5]. They represent a phenotype “within” the patient
below the level of overt behavioural or psychopathologi-
cal symptoms. Five criteria for an endophenotype have
been put forward: (i) association with illness (higher
rates of endophenotype in people with the illness than
that found in the general population); (ii) state
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of the disease state); (iii) familial association (the endo-
phenotype is present at higher rates in unaffected family
members than in the general population); (iv) co-segre-
gation (higher prevalence of the endophenotype in ill
relatives of ill probands than in well relatives of ill pro-
bands); and (v) heritability (the extent of variation of the
endophenotype that is attributable to the genetic varia-
tion) [6]. It has been proposed that endophenotypes
may be of particular value to genetic research on mental
disorders because they are more closely related to
underlying gene expression than is psychopathology [7].
For example, endophenotypes could be used for the dis-
covery of genes associated with schizophrenia [8].
Neurological soft signs are a potential endophenotype
for schizophrenia, because: they are common in people
with the disorder (ranging from 50 to 65% of people
with schizophrenia [1], predate the onset of the disorder
[9], and can be plausibly linked to the underlying brain
abnormalities postulated by the neurodevelopmental
theory of schizophrenia [1,10]. It has been established,
in a systematic review and meta-analysis [3], that neuro-
logical soft signs in schizophrenia meet two criteria for
an endophenotype: association with illness (because they
occur much more frequently in people with schizophre-
nia than in controls); and state-independence (because
they are present whether or not the illness is active).
This systematic review and meta-analysis aimed to
determine how far soft signs in schizophrenia met a
further criterion for an endophenotype, namely familial
association. It was hypothesized that if familial associa-
tion were present then neurological soft signs would be:
(a) more common in first-degree relatives of people
with schizophrenia than in controls; and (b) more com-
mon in people with schizophrenia than in their first-
degree relatives.
Methods
Data Sources
The search strategy aimed to identify all studies that had
conducted three-way comparisons of neurological soft
signs between people with schizophrenia, their first-
degree relatives, and normal controls. People with schi-
zophrenia were defined as having been given a diagnosis
of schizophrenia, or schizophrenia-like disorder on the
basis of a standardised diagnostic assessment. Three-way
comparisons were considered more suitable for testing
our hypotheses than two way comparisons because dif-
ferences in effect sizes between comparisons (e.g. rela-
tives versus controls and schizophrenia versus relatives)
would not be confounded by the use of different assess-
ment techniques, raters, or instruments.
Unlike randomised controlled trials, such comparative
studies are not well indexed; therefore a search strategy
was generated empirically by examining the indexing of
relevant papers from the authors’ personal databases
and from the references of previously published reviews
[1,11,12]. This search strategy was designed to be sensi-
tive rather than specific, and was applied to the follow-
ing databases: EMBASE, OVID-MEDLINE and
PsycINFO. The sensitivity of the search was confirmed
by checking the reference lists of the identified studies
and reviews to ensure that no relevant papers had been
omitted. Where an omission had occurred, the indexing
of the omitted paper was scrutinized, and the search
strategy was modified and re-run. This process contin-
ued until no new papers were identified. The original
search performed in September 2009 was updated again
in April 2011 (see table 1).
Study Selection
KN screened each abstract, and copies of any potentially
relevant articles were obtained. KN and DG independently
Table 1 Search strategy
1 neurological$.ab, kw, rt, tm, ti. 278114
2 (neuro$ adj3 sign#).ab, kw, rt, tm, ti. 22797
3 soft sign#.ab, kw, rt, tm, ti. 1109
4 (soft adj2 neuro$).ab, kw, rt, tm, ti. 1411
5 NSS.ab, kw, rt, tm, ti. 2494
6 SNS.ab, kw, rt, tm, ti. 4661
7 1 or 2 or 3 or 4 or 5 or 6 294985
8 exp schizophrenia/ 244555
9 (schizo$ or psychotic$ or psychosis or psychoses or hebephreni$ or oligophreni$).ab, kw, rt, ti. 365517
10 ((CHRONIC$ or SEVER$) adj5 MENTAL$ adj5 (ILL$ or DISORDER$)).ab, kw, rt, ti. 18088
11 first episode.ab, kw, rt, ti. 15961
12 Prodrom$.ab, kw, rt, ti. 9987
13 8 or 9 or 10 or 11 or 12 434722
14 7 and 13 8678
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the studies between them were resolved by discussion.
Unresolved disagreements between KN and DG were
resolved by discussion with the third reviewer (MM). Stu-
dies were included if they compared levels of soft signs
between normal controls, first-degree relatives of people
with schizophrenia and people with schizophrenia within
the same study design.
Data Extraction
The outcome variable for the review was the mean
number of neurological soft signs. Data were excluded
i f :t h e yo n l yr e f e r r e dt os u b s e t so ft h es o f ts i g n sf a m i l y
(such as frontal release signs), they were combined
with numbers of hard signs, or were reported exclu-
sively in a categorical format (as there is no universally
agreed cut off point for presence or absence of soft
signs) [13].
Several scales are available for rating the number of
soft signs, the most well known being: the Neurological
Evaluation Scale [2], the Condensed Neurological Exam-
ination or Rossi Scale [14], and the Standardised Neuro-
logical Examination [15]. Since there is considerable
overlap between these scales, data were included if any
of these three measures were used [13].
Demographic and study variables were extracted and
reported in tabular form, including: age, sex, number of
years in education, illness duration, type of control
group, and type of relative (primary or secondary
degree, or if primary degree: sibling, offspring, parent or
mixed group). In addition, each included study was
rated on three quality criteria: evidence of inter-rater
reliability on the ratings of soft signs; rater blind to the
status of the participant (although adequate blinding is
difficult to attain and this bias cannot be fully elimi-
nated); and degree of age matching between comparison
groups (see table 2). Data were extracted independently
by two reviewers (KN and DG) and crosschecked by the
double entry method. Disagreements were resolved by
discussion and involvement of the third reviewer (MM).
Data synthesis
The data were analysed using Comprehensive Meta-
Analysis version 2, a dedicated meta-analysis pro-
gramme (BioStat, Inc, Englewood, NJ). The analysis was
based on all included studies and consisted of three
comparisons: first-degree relatives of people with schizo-
phrenia versus normal controls; people with schizophre-
nia versus normal controls; and people with
schizophrenia versus first-degree relatives.
The standardized mean difference was calculated for
each comparison. The standardized mean difference
(SMD) is a clinically useful effect size defined as the dif-
ference in means between two groups standardized by
dividing by the with-in groups’ pooled standard devia-
tion. The SMD effect size can be interpreted as the
average percentile standing of the mean in the compari-
son group relative to the mean in the control group.
Thus, an effect size of “0” indicates that the mean in the
comparison group is at the 50
th percentile of the control
group, and the distribution of scores in the comparison
group completely overlaps with the distribution of
scores in the control group. An effect size of 0.8 indi-
cates that the mean in the comparison group is at the
79
th percentile of the control group, and shows a non-
overlap of nearly 50% in the distribution of scores
between the two groups. Cohen has defined a standar-
dised mean difference of 0.2 as small, 0.5 as medium,
and 0.8 as large [16].
The results of the comparisons were illustrated in a
Forest plot, in which the standardised mean difference
for each study and the associated 95% confidence inter-
vals were plotted on a horizontal axis ranging from -1
to 4. All comparisons were tested for heterogeneity
using the I
2 statistic. When significant heterogeneity was
present, the cumulative standardised mean difference
was calculated using random effects. When significant
heterogeneity was present, and sufficient studies were
available (greater than 9), meta-regression was used to
determine whether the heterogeneity could be explained
by moderator variables, such as: age, number of years in
education, use of anti-psychotic medication or illness
duration.
Scores on measures of neurological soft signs are
thought to increase with age [14,17], and may be sensi-
tive to inadequate rater training, or rater bias. Therefore
sensitivity analyses were conducted for each of the three
comparisons that excluded studies that: had more than
a decade age difference between comparison groups;
failed to provide evidence of inter-rater reliability; or
used raters that were not blind to the group allocation
of participants. The possibility of publication bias was
examined using the Orwin fail-safe N.
Results
The search strategy identified 8678 articles, of which
120 referred to studies that were thought to potentially
satisfy the inclusion criteria. After obtaining the full text
of these articles, it was found that 105 referred to stu-
dies that did not meet inclusion criteria. Seven studies,
described in 15 articles, met inclusion criteria and
offered data for the meta-analysis [14,18-31] (for details
see study flowchart Figure 1).
All seven included studies compared levels of soft
signs amongst people with schizophrenia, relatives, and
normal controls, within the same design, using the same
assessment method and the same raters. The partici-
pants in the included studies comprised: 558 people
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Study
reference
NSS
Scale
Blindness# Schizophrenia Group Relatives Group Control Group
Disorder
(Diagnostic
method)
N Mean
Age
Male
%
Years in
education
Illness
duration in
years
NSS
Mean
(SD)
Relative
Type
N Mean
Age
Male
%
Years in
education
NSS
Mean
(SD)
Control
Type
N Mean
Age
Male
%
Years in
education
NSS
Mean
(SD)
Compton et
al 2007 [24]
NES No Scz or scz-like
(SCID-DSMIV)
73 32.4 58% 13.1 nr 20.7
(10.6)
Mixed 44 43.2 16% 13.1 15.9 (9) Waiting area
and public
54 44.8 50% 12.3 14.3
(8.3)
Egan et al
2001 [25]
NES Yes Scz (DSMIV 115 35.9 83% 15.4 nr 6.8
(4.24)
Siblings 185 36.3 43% 15.4 3.05
(2.82)
Normal
Volunteers
88 33.4 42% 15.9 2.8
(2.29)
Gourion et
al 2003 [26]
SNE No Scz or scz-like
(DSMIV)
18 28.2 67% 5.5 9.1 18.7
(9.4)
Parents 36 60.4 50% 5.5 16 (5.8) Hospital Staff
or volunteers
42 26.6 38% 7.1 3.9 (2.8)
Ismail et al
1998 [27]
CNE No Scz (DSMIIITR) 60 38.2 73% nr 14.8 3.25
(3.31)
Siblings 21 37.9 nr nr 1.33
(2.01)
Normal
workers
75 35.9 79% nr 0.2
(0.54)
Mechri et al
2009 [28]a
SNE No Scz (DIGS) 69 28.2 74% 12.4 6.1 15 (7.9) Siblings 43 29.2 40% 13.8 8 (4) Hospital
Volunteer
108 28.2 63% 13.5 5.8 (3.3)
Mechri et al
2009 [28]b
SNE No Scz (DSMIV) 66 31.2 76% 8.5 nr 19.5
(5.2)
Siblings 31 32.2 71% 10.6 10.8
(3.4)
Hospital
Volunteer
60 30.8 67% 9.8 4.2 (2.1)
Rossi et al
1990 [14]
CNE Yes Scz (DSMIII) 58 34.8 64% 6.9 11.1 12.63
(4.79)
Mixed 31 39.2 58% 6.9 9.8
(2.42)
Family
Practice
38 36.2 58% 8.5 4.07
(2.53)
Yazici et al,
2002 [29]
NES No Scz (DSMIV) 99 31.4 48% 10.9 8.9 20.47
(10.07)
Siblings 80 31.6 53% 10.9 10.6
(7.23)
Normal
Volunteers
59 31.6 53% 10.8 6.66
(5.37)
NSS - Neurological soft signs, NES - Neurological Evaluation Scale, SNE - Standardised Neurological Examination, CNE - Condensed Neurological Examination, Scz - Schizophrenia, Scz-like - Schizophrenia-like disorders,
DSM- Diagnostic and Statistical Manual, SCID- Structured Clinical Interview for DSM, SCAN- Structured Clinical Assessment in Neuropsychiatry, DIGS - Diagnostic Interviews for Genetic Studies, nr - not reported, # - All
studies reported inter-rater reliability.
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8with schizophrenia or schizophrenia-like disorders, 471
first-degree relatives (there were no studies of second
degree relatives), and 524 normal controls (see table 2).
One study [28] included two independent samples from
different countries (France and Tunisia). Within the
meta-analysis, this study was treated as two separate
studies. Of the remaining six studies the country of ori-
gin of two studies was USA [24,25] and there was one
study each from Sweden [27], Italy [14], Turkey [29]
and France [26].
The Neurological Evaluation Scale [2] was used in 3
studies, whilst the Rossi Scale [14] and the Standardised
Neurological Examination [15] were each used in 2 stu-
dies (see table 2).
The group of first -degree relatives was categorised as
a “mixed” group in 2 studies [14,24] as they included a
combination of offspring, siblings and/or parents. In the
first of these studies [14], the ages of all three groups
were similar, suggesting that the relatives group were
principally siblings and that there was little chance of an
age difference between groups confounding the compar-
ison. In the second study [24], the relatives group were
11 years older on average than the schizophrenia group,
whilst the control group were 12 years older on average.
This suggested a risk of an age confound, as neurologi-
cal soft signs could increase with age. In 4 studies the
first degree relatives group consisted only of siblings
[25,27-29] and in one study consisted only of parents
[26]. In this study, parents were on average 32 years
older than people with schizophrenia, whereas controls
were 10 years older, again suggesting the possibility of
an age confound.
Neurological soft signs in first-degree relatives versus
controls
This comparison comprised 995 participants from seven
studies (see Figure 2). Whilst all seven studies showed
the same direction of effect, heterogeneity between stu-
dies was significant (I
2 94.9, p < 0.001), so the data were
analysed using a random effects model. As the compari-
son included less than 9 studies, meta-regression was
not attempted. The pooled SMD (random effects model)
was 1.24 (95% confidence interval 0.59 to 1.89). This
indicated a large and significant effect size. This finding
was stable (SMD 1.03 95% confidence interval 0.42 to
1.63, N = 917) when a sensitivity analysis was conducted
excluding data from one study where there was greater
than 10 year age gap between first-degree relatives and
controls [26]. However it was not significant (SMD 1.19
95% confidence interval -0.99 to 3.35, N = 342) after the
additional exclusion of 5 unblinded studies [24,26-29].
Neurological soft signs in schizophrenia versus controls
This comparison comprised data on 1082 subjects from
seven studies. Whilst all seven studies showed the same
direction of effect, heterogeneity between studies was
significant (I
2 93.1, p < 0.001), so the data were analysed
using a random effects model. As no comparison
included more than 7 studies, meta-regression was not
attempted. The pooled standardized mean difference
(random effects model) was 1.83 (95% confidence inter-
val 1.28 to 2.38), indicating a large and significant effect
size. This finding was stable (SMD 2.0 95% confidence
interval 1.44 to 2.56, N = 955) when a sensitivity analy-
sis was conducted excluding data from one study where
there was greater than 10 year age gap between people
with schizophrenia and controls [24]. It was also stable
(SMD 1.60 95% confidence interval 0.64 to 2.56, N =
299) to a sensitivity analysis that, in addition, excluded 5
unblinded studies [24,26-29].
Neurological soft signs in schizophrenia versus first
degree relatives
This comparison comprised data on 1040 participants
from seven studies. Whilst all seven studies showed the
same direction of effect, heterogeneity between studies
was significant (I
2 74.6, p < 0.001), so the data were ana-
lysed using a random effects model. As no comparison
included more than 7 studies, meta-regression was not
attempted. The pooled standardised mean difference
was 0.92 (95% confidence interval 0.64 to 1.12), indicat-
ing a large and significant effect size. This finding was
stable (SMD 1.07 95% confidence interval 0.79 to 1.34,
N = 869) when a sensitivity analysis was conducted
excluding data from 2 studies where there was greater
than 10 year age gap between the group of people with
schizophrenia and their first-degree relatives [24,26]. It
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ϳƐƚƵĚŝĞƐĚĞƐĐƌŝďĞĚŝŶϭϱĂƌƚŝĐůĞƐ͘

ZĞƋƵĞƐƚĞĚĂƌƚŝĐůĞƐĞǆĐůƵĚĞĚ
EсϭϬϱ
ηĞǆĐůƵĚĞĚĨŽƌĨŽůůŽǁŝŶŐƌĞĂƐŽŶƐ͗
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ǀĞƌƐƵƐĐŽŶƚƌŽůƐ
ŶсϳŽĨĨĞƌŝŶŐĚĂƚĂŽŶůǇŽŶƌĞůĂƚŝǀĞƐǀĞƌƐƵƐ
ĐŽŶƚƌŽůƐ
ŶсϭŽĨĨĞƌŝŶŐĚĂƚĂŽŶůǇŽŶƐĐŚŝǌŽƉŚƌĞŶŝĂ
ǀĞƌƐƵƐƌĞůĂƚŝǀĞƐ͘
Figure 1 Flowchart of meta-analysis.
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Page 5 of 8was also stable (SMD 0.93 95% confidence interval 0.54
to 1.32, N = 389) to a sensitivity analysis that, in addi-
tion, excluded 5 unblinded studies [24,26-29].
Publication bias
Publication bias was assessed using the Orwin fail-
safe N. The Orwin fail safe N estimates the number
of unpublished studies that would be required to shift
the effect size towards a null result [32]. The test was
used to estimate the number of missing studies with
an SMD of 0 that would be required to bring the
overall SMD to under 0.2, which Cohen defined as a
small but significant difference. For the comparison of
schizophrenia versus normal controls this would
require 54. Likewise, for schizophrenia versus first
degree relatives and first-degree relatives versus
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Neurological soft signs in people with schizophrenia, their relatives and normal controls 
-1 0 1 2 3 4
            Pooled SMD Scz vs Rel 0.92 (0.64, 1.20)
Yazici et al, 2002 1.11 (0.79, 1.42)
Rossi et al, 1990 0.69 (0.24, 1.13)
Mechri et al, 2009(b) 1.85 (1.35, 2.35)
Mechri et al, 2009(a) 1.05 (0.64, 1.45)
Ismail et al, 1998 0.63 (0.13, 1.14)
Gourion et al, 2003 0.38 (-0.19, 0.95)
Egan et al, 2001 1.09 (0.84, 1.34)
Compton et al, 2007 0.48 (0.10, 0.86)
      Schizophrenia versus relatives 
            Pooled SMD Scz vs NC 1.83 (1.28, 2.38)
Yazici et al, 2002 1.60 (1.23, 1.97)
Rossi et al, 1990 2.11 (1.61, 2.62)
Mechri et al, 2009(b) 3.79 (3.21, 4.38)
Mechri et al, 2009(a) 1.65 (1.31, 2.00)
Ismail et al, 1998 1.36 (0.98, 1.74)
Gourion et al, 2003 2.64 (1.91, 3.37)
Egan et al, 2001 1.13 (0.83, 1.43)
Compton et al, 2007 0.66 (0.30, 1.02)
Schizophrenia versus controls
  Pooled SMD Rel vs NC 1.24 (0.59, 1.89)
Yazici et al, 2002 0.61 (0.26, 0.95)
Rossi et al, 1990 2.31 (1.70, 2.92)
Mechri et al, 2009(b) 2.53 (1.96, 3.10)
Mechri et al, 2009(a) 0.63 (0.27, 0.99)
Ismail et al, 1998 1.08 (0.58, 1.59)
Gourion et al, 2003 2.72 (2.11, 3.34)
Egan et al, 2001 0.09 (-0.16, 0.35)
Compton et al, 2007 0.19 (-0.21, 0.58)
Effect size (95% CI)
 Relatives versus controls
Figure 2 Forest plot of neurological soft signs.
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respectively.
Discussion
It was hypothesized that if soft signs showed evidence of
familial association, then they would be more common in
people with schizophrenia versus their first-degree rela-
tives; and in first-degree relatives versus normal controls.
Both these hypotheses were confirmed. As anticipated, it
was also found that soft signs were more common in
people with schizophrenia than normal controls. Thus, in
summary, soft signs appear to be distributed across peo-
ple with schizophrenia and their first-degree relatives in a
manner that is consistent with familial association.
A key limitation of this review was the finding of sig-
nificant heterogeneity across all comparisons. The var-
iance among studies could be due to factors such as
variation among sample size of studies, source of normal
controls, kind of first degree relatives, scales used and
clinical factors such as being on medication. Insufficient
studies were available to permit investigation of this het-
erogeneity using meta-regression. Likewise, higher
s c o r e sf o rs o m es i g n si np a t i e n t sm a yb ed u et ou s eo f
anti-psychotic medication and we could not conduct
moderator analysis exploring the extent of its effects.
Despite some similar labels, it should be kept in mind
while interpreting the meta-analysis that the rating and
the tasks that correspond to the individual NSS items
vary between the different scales. However, all studies in
the review had the same direction of effect, and the
findings were stable to analysis using a random effects
model. Moreover, with the exception of one comparison
(first degree relatives versus controls, where the effect
size remained stable but no longer statistically signifi-
cant), the findings were also stable to a rigorous sensi-
tivity analysis which ruled out those studies with poor
age matching of controls, lack of reliability testing, and
unblinded raters. Thus it is probable that the findings
reflect true differences between the comparison groups,
rather than bias or fundamental differences in study
methodology. A further limitation is the possibility that
the findings could be explained by publication bias.
Tests for publication bias suggest that this is unlikely,
but it cannot be ruled out completely.
Hence, the findings of this review add weight to the
idea that neurological soft signs are an endophenotype of
schizophrenia. Contrary, to other developmental markers
such as ‘minor physical anomalies’ were early environ-
mental factors are indicated, soft signs reflect familial
association [26]. There is evidence to suggest that certain
neurological soft signs correlate with region-specific
structural brain deficits in people with schizophrenia
[33,34]. Future research should explore the potential of
these individual signs as endophenotype of schizophrenia.
Neurological soft signs can be elicited quickly, reliably
and cheaply [13], they could be used in ordinary clinical
settings to establish that an individual had progressed
along the neuro-developmental pathway to schizophre-
nia. There is evidence to suggest association of neurolo-
gical soft signs in relatives with schizotypal personality
scores, symptom severity and neuropsychological mea-
sures [30]. The presence of higher rates of soft signs has
the potential to augment the predictive power of psy-
chopathological tests for the prodrome of schizophrenia,
such as: the SIP/SOPS [35], Comprehensive Assessment
of At Risk Mental States (CAARMS) [36], or Basic
Symptoms [37]. Our meta-analysis highlights the mean-
ing of neurological soft signs in the context of neurode-
velopmental theory of schizophrenia. Neurological soft
signs have important clinical implications and they open
an avenue for future research.
Conclusion
Neurological soft signs show a pattern of familial asso-
ciation in schizophrenia that is compatible with the sta-
tus of an endophenotype for the disorder. The findings
are based on a small number of studies. There is a need
for more studies using a consensual rating tool and
homogeneous sample to establish that neurological soft
signs are an endophenotype of schizophrenia. Prospec-
tive diagnostic studies are required to establish how far
the identification of soft signs in at risk patients can
augment the predictive power of established psycho-
pathological tests.
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